FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB

Washington, D.C. 20549

### BARR PHARMACEUTICALS INC

Form 4

December 15, 2008

				vvasningt	on, D.C.	20549			I	Numbe	er:			
	Check this box if no longer		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF						Expire	S:	uary 31, 2005			
	subject to Section 16.				SECURITIES SECURITIES						ited averag n hours pe	r		
Form 4 or Form 5  obligations may continue.  See Instruction 1(b).  Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									1934,	respon	ise	0.5		
(Print	t or Type Respo	onses)												
1. Name and Address of Reporting Person * SEAVER PETER				Symbol	•				5. Relationship of Reporting Person(s) to Issuer					
				BARR PHAR [BRL]	BARR PHARMACEUTICALS INC [BRL]				(Check all applicable)					
D.A.	(Last) (First) (Middle)			(Month/Day/Yea	3. Date of Earliest Transaction (Month/Day/Year)				Director 10% Owner Specify below) Other (specify below)					
	RR PHARM C., 400 CHES AD			12/11/2008					Iı	nsider				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person						
WOODCLIFF LAKE, NJ 07677				Form filed by Mo Person					e than C	One Reporting	g			
	(City)	(State)	(Zip)	Table I - No	on-Derivati	ve Securit	ies Ac	quired, Di	sposed of, o	r Bene	ficially Ow	vned		
1.Tit (Inst	tle of Security r. 3)		saction Date /Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	4. Securition Dispose (Instr. 3, 4)	ed of (4 and 5 (A) or	D)	5. Amount Securities Beneficiall Owned Following Reported Transaction (Instr. 3 and	y I I (n(s) (	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Bar Pha Inc.	rmaceuticals	, 12/11/	/2008		M	10,000	A	\$ 48.84	10,000	]	D			
Bar Pha Inc.	rmaceuticals	, 12/11/	/2008		M	10,000	A	\$ 39.76	20,000	]	D			
Bar Pha Inc.	rmaceuticals	, 12/11/	/2008		S	3,300	D	\$ 65	16,700	]	D			

**OMB APPROVAL** 

Number:

3235-0287

Barr Pharmaceuticals, Inc.	12/11/2008	S	3,000	D	\$ 65.01	13,700	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	400	D	\$ 65.005	13,300	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	900	D	\$ 65.007	12,400	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	300	D	\$ 65.008	12,100	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	200	D	\$ 65.015	11,900	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	3,700	D	\$ 65.02	8,200	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	100	D	\$ 65.025	8,100	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	700	D	\$ 65.03	7,400	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	500	D	\$ 65.035	6,900	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	1,200	D	\$ 65.04	5,700	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	300	D	\$ 65.047	5,400	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	900	D	\$ 65.05	4,500	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	200	D	\$ 65.06	4,300	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	600	D	\$ 65.07	3,700	D
Barr Pharmaceuticals,	12/11/2008	S	700	D	\$ 65.08	3,000	D

Inc.						
Barr Pharmaceuticals, Inc.	12/11/2008	S	600	D	\$ 65.11 2,400	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	200	D	\$ 65.12 2,200	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	200	D	\$ 65.15 2,000	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	400	D	\$ 65.17 1,600	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	300	D	\$ 65.18 1,300	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	300	D	\$ 65.19 1,000	D
Barr Pharmaceuticals, Inc.	12/11/2008	S	1,000	D	\$ 65.22 0	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

 $\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$ 

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of iorDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	A or N
Director Stock Plan	\$ 48.84	12/11/2008		M	1	0,000	05/17/2007	10/09/2016	Barr Pharmaceuticals, Inc.	1

Director Barr Stock \$ 39.76 12/11/2008 M 10,000 11/21/2008 05/15/2018 Pharmaceuticals, Plan Inc.

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

**SEAVER PETER** 

BARR PHARMACEUTICALS, INC. 400 CHESTNUT RIDGE ROAD WOODCLIFF LAKE, NJ 07677

Insider

## **Signatures**

S/S William T. McKee as Attorney-in-Fact for Peter Seaver

12/15/2008

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

#### **Remarks:**

This is a multi-filing. This is Form 2 of 2 for Peter Seaver's activity on 12/11/2008

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 4